Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Linda Burghardt, PhD, a researcher in Great Neck, New York, started taking semaglutide because her doctor thought it might ...

CMS has launched the BALANCE Model, a five-year test to lower costs & expand Medicare access to GLP-1 weight-loss drugs while ...

As Indiana enters 2026, a major shift in the healthcare landscape is promising to make high-demand weight-loss medications more accessible to millions. With ...

Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline ...

Now the arrival of a Wegovy pill in U.S. pharmacies feels like a line in the sand between the first and second era of ...

Danish pharmaceutical giant Novo Nordisk has officially launched its once-daily Wegovy weight-loss pill in the United States, ...

Danish drugmaker Novo Nordisk is launching its once-daily Wegovy pill in the United States on Monday, offering doses of 1.5 ...

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with ...

Consumers must be proactive in asking about eligibility to avoid bills that could exceed $1,000 for a five-day supply, ...

The new year could bring dramatic changes to health care. Michigan doctors highlight the top 5 things they expect to see in ...

There are a lot of predictions that artificial intelligence doctors are coming soon. A look at the investment market confirms ...